Pfizer reports Phase II data for 25vPnC infant vaccine candidate

​

Pfizer has reported data from a Phase II trial assessing PF-07872412, its investigational 25-valent pneumococcal conjugate vaccine candidate, in infants.

The post Pfizer reports Phase II data for 25vPnC infant vaccine candidate appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.